Muromonab CD3 oral (Therapix Biosciences)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMuromonab CD3 oral (Therapix Biosciences)
Drug Alias NameaCD-3-MAbTRX-318aCD-3Oral-anti-CD3-MAbOKT-3-oral-NasVax
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsT cell apoptosis inducers
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandAustria
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe Brigham and Women's Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInspira Medical Ab
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A